192 related articles for article (PubMed ID: 28791783)
1. Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.
Zeineddine HA; Girard R; Cao Y; Hobson N; Fam MD; Stadnik A; Tan H; Shen J; Chaudagar K; Shenkar R; Thompson RE; McBee N; Hanley D; Carroll T; Christoforidis GA; Awad IA
J Magn Reson Imaging; 2018 Apr; 47(4):1133-1138. PubMed ID: 28791783
[TBL] [Abstract][Full Text] [Related]
2. Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.
Girard R; Fam MD; Zeineddine HA; Tan H; Mikati AG; Shi C; Jesselson M; Shenkar R; Wu M; Cao Y; Hobson N; Larsson HBW; Christoforidis GA; Awad IA
J Neurosurg; 2017 Jul; 127(1):102-110. PubMed ID: 27494817
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping.
Tan H; Liu T; Wu Y; Thacker J; Shenkar R; Mikati AG; Shi C; Dykstra C; Wang Y; Prasad PV; Edelman RR; Awad IA
Invest Radiol; 2014 Jul; 49(7):498-504. PubMed ID: 24619210
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.
Polster SP; Stadnik A; Akers AL; Cao Y; Christoforidis GA; Fam MD; Flemming KD; Girard R; Hobson N; Koenig JI; Koskimäki J; Lane K; Liao JK; Lee C; Lyne SB; McBee N; Morrison L; Piedad K; Shenkar R; Sorrentino M; Thompson RE; Whitehead KJ; Zeineddine HA; Hanley DF; Awad IA
Neurosurgery; 2019 Dec; 85(6):843-853. PubMed ID: 30476251
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations.
Tan H; Zhang L; Mikati AG; Girard R; Khanna O; Fam MD; Liu T; Wang Y; Edelman RR; Christoforidis G; Awad IA
AJNR Am J Neuroradiol; 2016 Jul; 37(7):1209-15. PubMed ID: 26965464
[TBL] [Abstract][Full Text] [Related]
6. Quantitative susceptibility mapping (QSM) as a means to monitor cerebral hematoma treatment.
Zhang Y; Wei H; Sun Y; Cronin MJ; He N; Xu J; Zhou Y; Liu C
J Magn Reson Imaging; 2018 Oct; 48(4):907-915. PubMed ID: 29380461
[TBL] [Abstract][Full Text] [Related]
7. Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling.
Hage S; Kinkade S; Girard R; Flemming KD; Kim H; Torbey MT; Huang J; Huston J; Shu Y; Selwyn RG; Hart BL; Mabray MC; Feghali J; Sair HI; Narvid J; Lupo JM; Lee J; Stadnik A; Alcazar R; Shenkar R; Hobson N; DeBiasse D; Lane K; McBee N; Treine K; Ostapkovich N; Wang Y; Thompson RE; Mendoza-Puccini C; Koenig J; Carroll T; Hanley DF; Awad IA
medRxiv; 2023 Jun; ():. PubMed ID: 37333396
[TBL] [Abstract][Full Text] [Related]
8. Reliable? The Value of Early Postoperative Magnetic Resonance Imaging after Cerebral Cavernous Malformation Surgery.
Chen B; Göricke S; Wrede K; Jabbarli R; Wälchli T; Jägersberg M; Sure U; Dammann P
World Neurosurg; 2017 Jul; 103():138-144. PubMed ID: 28391022
[TBL] [Abstract][Full Text] [Related]
9. Quantitative susceptibility mapping across two clinical field strengths: Contrast-to-noise ratio enhancement at 1.5T.
Ippoliti M; Adams LC; Winfried B; Hamm B; Spincemaille P; Wang Y; Makowski MR
J Magn Reson Imaging; 2018 Nov; 48(5):1410-1420. PubMed ID: 29659131
[TBL] [Abstract][Full Text] [Related]
10. Quantitative susceptibility mapping (QSM) minimizes interference from cellular pathology in R2* estimation of liver iron concentration.
Li J; Lin H; Liu T; Zhang Z; Prince MR; Gillen K; Yan X; Song Q; Hua T; Zhao X; Zhang M; Zhao Y; Li G; Tang G; Yang G; Brittenham GM; Wang Y
J Magn Reson Imaging; 2018 Oct; 48(4):1069-1079. PubMed ID: 29566449
[TBL] [Abstract][Full Text] [Related]
11. Preconditioned total field inversion (TFI) method for quantitative susceptibility mapping.
Liu Z; Kee Y; Zhou D; Wang Y; Spincemaille P
Magn Reson Med; 2017 Jul; 78(1):303-315. PubMed ID: 27464893
[TBL] [Abstract][Full Text] [Related]
12. Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth.
Girard R; Zeineddine HA; Koskimäki J; Fam MD; Cao Y; Shi C; Moore T; Lightle R; Stadnik A; Chaudagar K; Polster S; Shenkar R; Duggan R; Leclerc D; Whitehead KJ; Li DY; Awad IA
Circ Res; 2018 Jun; 122(12):1716-1721. PubMed ID: 29720384
[TBL] [Abstract][Full Text] [Related]
13. Surgical Management and Long-Term Seizure Outcome After Surgery for Temporal Lobe Epilepsy Associated with Cerebral Cavernous Malformations.
Yang PF; Pei JS; Jia YZ; Lin Q; Xiao H; Zhang TT; Zhong ZH
World Neurosurg; 2018 Feb; 110():e659-e670. PubMed ID: 29175574
[TBL] [Abstract][Full Text] [Related]
14. Quantitative susceptibility map analysis in preterm neonates with germinal matrix-intraventricular hemorrhage.
Tortora D; Severino M; Sedlacik J; Toselli B; Malova M; Parodi A; Morana G; Fato MM; Ramenghi LA; Rossi A
J Magn Reson Imaging; 2018 Nov; 48(5):1199-1207. PubMed ID: 29746715
[TBL] [Abstract][Full Text] [Related]
15. Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations.
Mikati AG; Tan H; Shenkar R; Li L; Zhang L; Guo X; Larsson HB; Shi C; Liu T; Wang Y; Shah A; Edelman RR; Christoforidis G; Awad I
Stroke; 2014 Feb; 45(2):598-601. PubMed ID: 24302484
[TBL] [Abstract][Full Text] [Related]
16. Automated algorithm for counting microbleeds in patients with familial cerebral cavernous malformations.
Zou X; Hart BL; Mabray M; Bartlett MR; Bian W; Nelson J; Morrison LA; McCulloch CE; Hess CP; Lupo JM; Kim H
Neuroradiology; 2017 Jul; 59(7):685-690. PubMed ID: 28534135
[TBL] [Abstract][Full Text] [Related]
17. Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.
Girard R; Zeineddine HA; Fam MD; Mayampurath A; Cao Y; Shi C; Shenkar R; Polster SP; Jesselson M; Duggan R; Mikati AG; Christoforidis G; Andrade J; Whitehead KJ; Li DY; Awad IA
Transl Stroke Res; 2018 Feb; 9(1):34-43. PubMed ID: 28819935
[TBL] [Abstract][Full Text] [Related]
18. Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).
Polster SP; Cao Y; Carroll T; Flemming K; Girard R; Hanley D; Hobson N; Kim H; Koenig J; Koskimäki J; Lane K; Majersik JJ; McBee N; Morrison L; Shenkar R; Stadnik A; Thompson RE; Zabramski J; Zeineddine HA; Awad IA
Neurosurgery; 2019 Apr; 84(4):954-964. PubMed ID: 29660039
[TBL] [Abstract][Full Text] [Related]
19. MRI-based quantitative susceptibility mapping (QSM) and R2* mapping of liver iron overload: Comparison with SQUID-based biomagnetic liver susceptometry.
Sharma SD; Fischer R; Schoennagel BP; Nielsen P; Kooijman H; Yamamura J; Adam G; Bannas P; Hernando D; Reeder SB
Magn Reson Med; 2017 Jul; 78(1):264-270. PubMed ID: 27509836
[TBL] [Abstract][Full Text] [Related]
20. Deep gray matter iron measurement in patients with liver cirrhosis using quantitative susceptibility mapping: Relationship with pallidal T
Lee S; Nam Y; Jang J; Na GH; Kim DG; Shin NY; Choi HS; Jung SL; Ahn KJ; Kim BS
J Magn Reson Imaging; 2018 May; 47(5):1342-1349. PubMed ID: 28815906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
